Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must have metastatic or locally advanced cancer which has failed to respond to standard therapy or no therapy exists.~* If the participant is a female, she must be postmenopausal or if she is of childbearing potential she must have blood pregnancy tests during the study and be willing to use 2 methods of contraception.~* If the participant is male and has female partners of child-bearing potential, he must agree to use a medically acceptable method of contraception during the study and for 30 days after the last dose of study drug.~Exclusion Criteria:~* Participant has had chemotherapy, radiotherapy or biological therapy within the past 4 weeks.~* Participant is currently receiving other anti-cancer therapy.~* Participant is currently participating or has participated in a study with an investigation drug or device within the last 30 days.~* Participant has a primary central nervous system tumor or active brain metastases.~* Participant has a psychiatric disorder.~* Participant uses illegal drugs.~* Participant is pregnant or breastfeeding.~* Participant is known to be human immunodeficiency virus (HIV) positive.~* Participant has a known history of Hepatitis B or C.~* Participant has newly diagnosed diabetes.~* Participant has an active infection.~* Participant is unable to swallow capsules.~* Participant has received a blood transfusion with one week of study entry.~* Participant has a history of cardiac problems including heart failure, myocardial infarction, unstable angina, congestive heart failure or cardiac arrhythmia.~* Participant has a known sensitivity to the components of the study drug.~* Participant has not adequately recovered from any prior surgical procedure.~* Participant does not agree to refrain from use of herbal remedies and consumption of grapefruit juice for 2 weeks prior to and during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pt 1. Placebo/Ridaforolimus 100 mg; Pt 2. Ridaforolimus 40 mg (Type: EXPERIMENTAL): \[Pt 1, Day 1\]: Participants received a single dose of placebo (10 oral tablets) on Day 1 of Part 1. \[Pt 1, Day 2\]: Following completion of Part 1 / Day 1, participants received a single dose of ridaforolimus 100 mg (10 x 10 mg oral tablets) on Day 2 of Part 1. Following completion of Part 1 / Day 2, participants entered a washout period of ≥5 days before the first dose Part 2. \[Pt 2\]: Following completion of Part 1, participants received ridaforolimus 40 mg (4 x 10 mg oral tablets) given once daily (QD) for 5 consecutive days followed by 2 days off-drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).